metformin has been researched along with everolimus in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (73.08) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Steinman, TI | 1 |
| Eucker, J; Habbel, P; Liu, H; Possinger, K; Regierer, AC; Schefe, JH; Scholz, C; Schulz, CO; Zang, C | 1 |
| Akahori, H; Finn, AV; Habib, A; Karmali, V; Pachura, K; Polavarapu, R | 1 |
| De Loof, H; De Meyer, GRY; Martinet, W | 1 |
| Carlock, C; Chen, J; Chen, JS; Choi, HH; Chou, PC; Ensor, J; Esteva, FJ; Fraser Symmans, W; Fuentes-Mattei, E; Gully, C; Hortobagyi, GN; Lee, MH; Luo, Y; McKeehan, WL; Phan, L; Pusztai, L; Qi, Y; Shin, JH; Velazquez-Torres, G; Wu, Y; Yeung, SC; Zhang, F; Zhang, Y; Zhao, R | 1 |
| Beijnen, JH; Huitema, AD; Opdam, FL; Schellens, JH | 1 |
| Galani, V; Georgiou, I; Kitsou, C; Kosmas, IP; Lazaros, L; Markoula, S; Mynbaev, O; Peschos, D; Prapas, I; Prapas, N; Tournaye, H; Zikopoulos, A | 1 |
| Weintraub, K | 1 |
| Fan, C; Li, L; Sun, Y; Wang, Y; Wei, J | 1 |
| Buzzoni, R; Concas, L; de Braud, F; Femia, D; Formisano, B; Giacomelli, L; Leuzzi, L; Marceglia, S; Mazzaferro, V; Milione, M; Pusceddu, S; Vernieri, C | 1 |
| Desir, S; Dickson, EL; Geller, MA; Lou, E; Steer, CJ; Subramanian, S; Teoh, D; Thayanithy, V; Vogel, RI; Wong, P | 1 |
| Ariaans, G; Jalving, M; Jong, S; Vries, EG | 1 |
| Klümpen, HJ; Mathot, RA; Molenaar, RJ; Richel, DJ; van de Venne, T; Weterman, MJ; Wilmink, JW | 1 |
| Savage, N | 1 |
| Alfonso, F; Cequier, Á; Cubero-Gallego, H; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Jiménez-Quevedo, P; Montanya, E; Pinar, E; Romaguera, R; Roura, G; Sabaté, M; Tebé-Codorni, C; Teruel, L | 1 |
| Antonuzzo, L; Aroldi, F; Bajetta, E; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Buzzoni, R; Campana, D; Carnaghi, C; Catena, L; Cauchi, C; Cavalcoli, F; Cingarlini, S; Colao, A; Concas, L; Davì, MV; de Braud, F; De Divitiis, C; Delle Fave, G; Di Costanzo, F; Di Maio, M; Duro, M; Ermacora, P; Faggiano, A; Fazio, N; Femia, D; Fontana, A; Garattini, SK; Giacomelli, L; Giuffrida, D; Ibrahim, T; La Salvia, A; Lo Russo, G; Marconcini, R; Massironi, S; Mazzaferro, V; Milione, M; Ortolani, S; Panzuto, F; Perfetti, V; Prinzi, N; Puliafito, I; Pusceddu, S; Razzore, P; Ricci, S; Rinzivillo, M; Spada, F; Tafuto, S; Torniai, M; Vernieri, C; Zaniboni, A | 1 |
| Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ | 1 |
| Broaddus, RR; Coleman, RL; Fellman, BM; Iglesias, DA; Lu, KH; Slomovitz, BM; Soliman, PT; Westin, SN; Yates, MS; Yuan, Y; Zhang, Q | 1 |
| Goodwin, PJ; Madariaga, A; Oza, AM | 1 |
| Borson-Chazot, F; Forestier, J; Hue-Fontaine, L; Lemelin, A; Lombard-Bohas, C; Milot, L; Raverot, G; Robinson, P; Walter, T | 1 |
| Chen, MJ; Chen, SU; Chou, CH; Ho, HN; Huang, CC; Shun, CT; Wen, WF; Yang, YS | 1 |
| Endo, I; Haba, S; Hara, K; Hasegawa, S; Hosono, K; Ichikawa, Y; Kato, S; Kessoku, T; Kobayashi, N; Kubota, K; Kurita, Y; Kuwahara, T; Mizuno, N; Nakajima, A; Niwa, Y; Okuno, N; Sato, T; Shimizu, Y; Tokuhisa, M | 1 |
| Han, WK; Hong, SH; Hwang, HJ; Lee, KS; Park, SY; Yoon, YE | 1 |
| Asghari, F; Karimi, MH; Pourfathollah, AA | 1 |
4 review(s) available for metformin and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Polycystic kidney disease: a 2011 update.
Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan | 2012 |
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
Topics: Absorbable Implants; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Dyslipidemias; Everolimus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Macrophages; Metformin; Mice; Mice, Knockout; Plaque, Atherosclerotic; Rabbits; Receptors, LDL; Rupture, Spontaneous; Sirolimus; Swine; Tissue Scaffolds; TOR Serine-Threonine Kinases; Triglycerides | 2014 |
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Topics: Antineoplastic Agents; Comorbidity; Diabetes Mellitus; Everolimus; Humans; Hypoglycemic Agents; Metformin; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms | 2016 |
3 trial(s) available for metformin and everolimus
| Article | Year |
|---|---|
A phase Ib study of everolimus combined with metformin for patients with advanced cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Neoplasms; TOR Serine-Threonine Kinases | 2018 |
In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug Synergism; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Male; Metformin; Prospective Studies; Prosthesis Design; Time Factors; Tomography, Optical Coherence; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
19 other study(ies) available for metformin and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Autophagy; Breast Neoplasms; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Everolimus; Female; Humans; Metformin; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Metformin impairs endothelialization after placement of newer generation drug eluting stents.
Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Hypoglycemic Agents; Iliac Artery; Immunosuppressive Agents; Male; Metformin; Paclitaxel; Rabbits; Sirolimus; Thrombosis; Tubulin Modulators | 2013 |
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
Topics: Adipocytes; Adipokines; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Everolimus; Female; Humans; Kaplan-Meier Estimate; Metformin; Mice; Mice, Transgenic; Middle Aged; Obesity; Postmenopause; Prospective Studies; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcriptome | 2014 |
[Hyperglycaemia during treatment with everolimus].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Neoplasm Recurrence, Local; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Topics: AMP-Activated Protein Kinases; Animals; Capillary Permeability; Chorionic Gonadotropin; Erlotinib Hydrochloride; Everolimus; Female; Follicle Stimulating Hormone; Hormones; Infliximab; Metformin; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Reproductive Control Agents; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2015 |
Can We Stop Aging?
Topics: Aged, 80 and over; Aging; Animals; Bone Morphogenetic Proteins; Chronic Disease; Everolimus; Growth Differentiation Factors; Humans; Longevity; Metformin; Sirolimus | 2015 |
Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Activators; Everolimus; Female; Metformin; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Communication; Cell Line, Tumor; Cell Membrane; Coculture Techniques; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Hypoxia; Intercellular Junctions; Metformin; Microscopy, Confocal; Microscopy, Fluorescence, Multiphoton; Ovarian Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2016 |
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Everolimus; Female; Glucose; Glycolysis; Humans; Metformin | 2017 |
New tricks from old dogs join the fight against ageing.
Topics: Aging; Animals; Autophagy; Biomedical Research; Caenorhabditis elegans; Cellular Senescence; Diet, Healthy; DNA Damage; Dogs; Drosophila melanogaster; Everolimus; Exercise; Health; Heart; Humans; Immunity; Life Expectancy; Longevity; Metformin; Mice; Quality of Life; Rejuvenation; Saccharomyces cerevisiae; Sirolimus; Social Support; Stress, Psychological; Telomere Shortening; TOR Serine-Threonine Kinases | 2017 |
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Diabetes Mellitus, Type 2; Disease-Free Survival; Everolimus; Female; Humans; Hypoglycemic Agents; Italy; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Somatostatin; Time Factors; Treatment Outcome; Young Adult | 2018 |
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Everolimus; Female; Humans; Letrozole; Metformin; Middle Aged; Progression-Free Survival | 2020 |
Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
Topics: Diabetes Mellitus, Type 2; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Metformin | 2020 |
Metformin and everolimus in neuroendocrine tumours: A synergic effect?
Topics: Aged; Antineoplastic Agents; Cohort Studies; Diabetes Mellitus; Digestive System Neoplasms; Drug Synergism; Everolimus; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Middle Aged; Neuroendocrine Tumors; Progression-Free Survival | 2020 |
Metformin: a novel promising option for fertility preservation during cyclophosphamide-based chemotherapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cells, Cultured; Cyclophosphamide; Everolimus; Female; Fertility; Hypoglycemic Agents; Metformin; Mice; Mice, Inbred C57BL; Ovarian Follicle; Protective Agents; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2021 |
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
Topics: Aged; Everolimus; Humans; Metformin; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis | 2023 |
Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Kidney Neoplasms; Metformin; Mitochondrial Dynamics; Neoplasm Recurrence, Local | 2022 |
mTORC1 inhibition may improve T lymphocytes affected by aging.
Topics: Aged; Aging; Animals; Everolimus; Humans; Interleukin-2; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; T-Lymphocytes; TOR Serine-Threonine Kinases | 2023 |